Chen Yi, Tang Yu-Xing, Zeng Da-Tong, Wen Jia-Ying, Zhan Yan-Ting, Li Dong-Ming, He Rong-Quan, Huang Zhi-Guang, Chen Yu-Zhen, Wei Qiu-Yu, Chen Gang, Tang Yu-Lu, Li Hui
Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China.
Department of Pathology, Redcross Hospital of Yulin, Yulin, P.R. China.
Cancer Control. 2025 Jan-Dec;32:10732748251330059. doi: 10.1177/10732748251330059. Epub 2025 Apr 14.
BackgroundAnaphase-promoting complex subunit 1 (ANAPC1) is a regulator of cellular mitosis and an important factor in tumorigenesis. To date, a comprehensive assessment of the potential role, biological behaviours, and clinical significance of ANAPC1 in colorectal cancer (CRC) is still lacking.Materials and methodsThis study integrated 2329 mRNA expression data, single-cell RNA sequencing (scRNA-seq), and internal immunohistochemistry of 416 tissue samples to comprehensively evaluate the abnormal expression pattern of ANAPC1 in CRC. It also incorporated evidence from immune infiltration analysis, functional enrichment analysis, and weighted gene co-expression network analysis to explore the biological behaviour of ANAPC1 in CRC. In addition, in vitro cell biology experiments such as real-time polymerase chain reaction (RT-PCR), western blot (WB), cholecystokinin 8 (CCK-8), wound healing, cell cycle, and apoptosis assays were conducted to verify the potential effect of ANAPC1 on CRC cells.ResultsANAPC1 mRNA was significantly overexpressed in CRC tissue (SMD = 2.07, 95% CI 1.59-2.55, < .05) and malignant epithelial cells ( < .05). Validation at the protein level similarly confirmed the overexpression of ANAPC1 in CRC tissue ( < .05). ANAPC1 in CRC may play a role in abnormal ribosome biogenesis, DNA replication, ATP-dependent activity acting on DNA, nuclear division, chromosome segregation, and other pathways. In vitro experiments demonstrated that HCT-116 cells with ANAPC1 knockdown had reduced proliferation and migration abilities, increased cell apoptosis rate, and altered cell cycle distribution. In addition, CRC patients with low ANAPC1 expression were more likely to benefit from treatment with immune checkpoint inhibitors. ANAPC1 was significantly downregulated in malignant epithelial cells of CRC treated with PD-1 inhibitors ( < .05).ConclusionANAPC1 may have a positive impact on the development of CRC by being involved in pathways related to DNA replication, chromosome segregation, and ribosomes.
背景
后期促进复合物亚基1(ANAPC1)是细胞有丝分裂的调节因子,也是肿瘤发生的重要因素。迄今为止,仍缺乏对ANAPC1在结直肠癌(CRC)中的潜在作用、生物学行为及临床意义的全面评估。
材料与方法
本研究整合了2329个mRNA表达数据、单细胞RNA测序(scRNA-seq)以及416个组织样本的内部免疫组化,以全面评估ANAPC1在CRC中的异常表达模式。还纳入了免疫浸润分析、功能富集分析和加权基因共表达网络分析的证据,以探究ANAPC1在CRC中的生物学行为。此外,进行了实时聚合酶链反应(RT-PCR)、蛋白质免疫印迹(WB)、胆囊收缩素8(CCK-8)、伤口愈合、细胞周期和凋亡检测等体外细胞生物学实验,以验证ANAPC1对CRC细胞的潜在影响。
结果
ANAPC1 mRNA在CRC组织(标准化均数差=2.07,95%置信区间1.59-2.55,P<0.05)和恶性上皮细胞中显著过表达(P<0.05)。蛋白质水平的验证同样证实了ANAPC1在CRC组织中的过表达(P<0.05)。CRC中的ANAPC1可能在核糖体生物合成异常、DNA复制、作用于DNA的ATP依赖性活性、核分裂、染色体分离及其他途径中发挥作用。体外实验表明,敲低ANAPC1的HCT-116细胞增殖和迁移能力降低,细胞凋亡率增加,细胞周期分布改变。此外,ANAPC1表达低的CRC患者更可能从免疫检查点抑制剂治疗中获益。在用PD-1抑制剂治疗的CRC恶性上皮细胞中,ANAPC1显著下调(P<0.05)。
结论
ANAPC1可能通过参与与DNA复制、染色体分离和核糖体相关的途径,对CRC的发展产生积极影响。